Results 11 to 20 of about 284,504 (254)
Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo Published, JLR Papers in Press, October 22, 2007. [PDF]
Scavenger receptor class B type I (SR-BI) functions as an HDL receptor that promotes the selective uptake of cholesteryl esters (CEs). The physiological role of SR-BI in VLDL metabolism, however, is largely unknown.
M. Van Eck+6 more
semanticscholar +5 more sources
Very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. It binds triglyceride rich lipoprotein (TGRL) but not LDL, because it recognizes apolipoprotein (apo)E only but not apoB.
Sadao Takahashi
semanticscholar +5 more sources
ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis* [PDF]
ApoAV has been discovered recently as a novel modifier of triglyceride (TG) metabolism, but the pathways involved are currently unknown. To gain insight into the function of apoAV, adenovirus-mediated gene transfer of murine apoa5 to C57Bl/6 mice was ...
F. Schaap+8 more
semanticscholar +4 more sources
The very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. In vitro and in vivo studies have shown that VLDL receptor binds triglyceride (TG)-rich lipoproteins but not LDL, and functions as a ...
Sadao Takahashi+7 more
semanticscholar +5 more sources
Adrenal cell aldosterone production is stimulated by very-low-density lipoprotein (VLDL). [PDF]
Very low-density lipoproteins (VLDL) are a class of large lipoprotein synthesized in the liver. The key function of VLDL, in vivo, is to carry triglyceride from the liver to adipose tissue.
Yewei Xing+5 more
semanticscholar +4 more sources
When iodinated hypercholesterolemic plasma very low density lipoprotein (VLDL), chylomicrons or chylomicron remnants were injected intravenously, the apoB of chylomicrons and chylomicron remnants was removed more rapidly than apoB of hypercholesterolemic
Kathryn Haeflein Thompson+1 more
semanticscholar +3 more sources
VLDL receptor gene therapy for reducing atherogenic lipoproteins
Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low-density lipoprotein cholesterol (LDL-C), there is mounting evidence for the residual CVD risk attributed
Krauss, Ronald M+4 more
openaire +5 more sources
Postprandial lipoprotein metabolism: VLDL vs chylomicrons [PDF]
Since Zilversmit first proposed postprandial lipemia as the most common risk of cardiovascular disease, chylomicrons (CM) and CM remnants have been thought to be the major lipoproteins which are increased in the postprandial hyperlipidemia. However, it has been shown over the last two decades that the major increase in the postprandial lipoproteins ...
Akira Tanaka+13 more
openaire +4 more sources
Hydrolysis of VLDL triacylglycerol (TG) by lipoprotein lipase (LpL) is a major step in energy metabolism and VLDL-to-LDL maturation. Most functional LpL is anchored to the vascular endothelium, yet a small amount circulates on TG-rich lipoproteins. As circulating LpL has low catalytic activity, its role in VLDL remodeling is unclear. We use pre-heparin
Antonio Pérez+4 more
openaire +5 more sources
Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis [PDF]
Patients and animals with nephrotic syndrome and those with chronic renal failure (CRF) often exhibit hypertriglyceridemia and impaired very low-density lipoprotein (VLDL) clearance. Imai rats that were originally derived from Sprague-Dawley rats develop spontaneous proteinuria, hyperlipidemia, progressive renal insufficiency and histologic changes of ...
Nosratola D. Vaziri+4 more
openaire +3 more sources